The Janssen Pharmaceuticals drug Risperdal Consta (risperidone) has been approved by the U.S. Food and Drug Administration for people with Bipolar 1 disorder, the drug maker said Monday.
Risperdal Consta is the long-acting version of Risperdal, which was first FDA-approved more than a decade ago and is now sanctioned for Bipolar 1, schizophrenia and autism.
Type 1 bipolar disorder involves at least one manic episode, with or without a major depressive episode.
Approval of Risperdal Consta for Bipolar 1 was granted as a single therapy, or in combination with lithium or valproate, Janssen said in a news release.
As with similar antipsychotic drugs, the packaging for Risperdal Consta includes a warning that the drug is not approved for elderly people with dementia-related psychosis, and could increase their risk of death.
More information
The FDA has more about this drug's approval history.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
The Daily Reflector
|
Weather
|
Sports
|
Look
|
Business
|
Opinion
|
Classifieds
|
Site Map
Cars
|
Jobs
|
Homes
Copyright 2009 The Daily Reflector All rights reserved. - The Daily Reflector - Our Partners
By using this service, you accept the terms of our
visitor agreement
and
privacy policy. About our ads.
Registered site users, you may edit your profile.
Having trouble? Visit our
help & FAQ
Your comments
Post a Comment
Comments that include profanity, personal attacks or any other inappropriate material are prohibited. By using our site you agree to our ground rules and our terms of use. There could be a delay of up to 5 minutes before your comment appears.